Atossa Therapeutics (ATOS) said Tuesday that results from the ongoing phase 2 Evangeline trial showed that (Z)-endoxifen achieved target tissue concentrations and demonstrated substantial tumor suppression in premenopausal women with a type of breast cancer.
The drug candidate was generally well tolerated with manageable side effects, according to the company.
Based on findings from the pharmacokinetic run-in phase, the company plans to proceed with an amended protocol comparing (Z)-endoxifen 40 milligrams per day with ovarian function suppression to exemestane plus OFS.
Recruitment for this cohort will start in 2025, the company added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.